The treat-to-target paradigm: a cross-sectional survey of current therapies and achieved metabolic control in 800 type 2 diabetic patients.

about

The treat-to-target paradigm: a cross-sectional survey of current therapies and achieved metabolic control in 800 type 2 diabetic patients.

Item

http://www.wikidata.org/entity/Q46636892

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

The treat-to-target paradigm: ...... 800 type 2 diabetic patients.

@en

The treat-to-target paradigm: ...... 800 type 2 diabetic patients.

@nl

type

Item

label

The treat-to-target paradigm: ...... 800 type 2 diabetic patients.

@en

The treat-to-target paradigm: ...... 800 type 2 diabetic patients.

@nl

prefLabel

The treat-to-target paradigm: ...... 800 type 2 diabetic patients.

@en

The treat-to-target paradigm: ...... 800 type 2 diabetic patients.

@nl

P1476

The treat-to-target paradigm: ...... 800 type 2 diabetic patients.

@en

P2093

M Buysschaert

http://www.w3.org/2001/XMLSchema#string

M P Hermans

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

P304

79-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1179/ACB.2005.015

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7677090

http://www.w3.org/2001/XMLSchema#string

P698

16082993

http://www.w3.org/2001/XMLSchema#string